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Abstract
Background: Chronic inflammation and autoimmunity likely contribute to the pathogenesis of abdominal
aortic aneurysms (AAAs). The aim of this study was to investigate the role of autoimmunity in the etiology
of AAAs using a genetic association study approach with HLA polymorphisms.
Methods: HLA-DQA1, -DQB1, -DRB1 and -DRB3-5 alleles were determined in 387 AAA cases (180
Belgian and 207 Canadian) and 426 controls (269 Belgian and 157 Canadian) by a PCR and single-strand
oligonucleotide probe hybridization assay.
Results: We observed a potential association with the HLA-DQA1 locus among Belgian males (empirical
p = 0.027, asymptotic p = 0.071). Specifically, there was a significant difference in the HLA-DQA1*0102
allele frequencies between AAA cases (67/322 alleles, 20.8%) and controls (44/356 alleles, 12.4%) in Belgian
males (empirical p = 0.019, asymptotic p = 0.003). In haplotype analyses, marginally significant association
was found between AAA and haplotype HLA-DQA1-DRB1 (p = 0.049 with global score statistics and p =
0.002 with haplotype-specific score statistics).
Conclusion: This study showed potential evidence that the HLA-DQA1 locus harbors a genetic risk
factor for AAAs suggesting that autoimmunity plays a role in the pathogenesis of AAAs.
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Background
Several distinct processes contribute to the pathologic
changes observed in abdominal aortic aneurysms (AAAs).
The most apparent of these are chronic inflammation,
destructive remodeling of the extracellular matrix, and
depletion of vascular smooth muscle cells [1]. Local
immune responses in the aorta are an important factor in
AAA pathogenesis. Autoimmunity has been proposed to
play a role in the pathogenesis of AAA [2,3]. Infiltration of
monocytes, macrophages, B-lymphocytes, plasma cells
and T-lymphocytes (including both CD4 and CD8 T-cells)
is commonly observed in the AAA walls [4]. Although the
actual factors (triggers) responsible for initiating the
chronic inflammatory response in the pathogenesis of
AAA are not yet known, HLA loci, particularly the HLA-
DQ and HLA-DR antigens, may play a key role.
The major histocompatibility complex (MHC) is located
at chromosome 6p21.31 and is the most gene-dense and
polymorphic region of the human genome identified so
far [5]. Historically, the MHC has been divided into three
regions: HLA class I, class II and class III. Although class I
antigens are present on the surface of most types of cells
in the human body, class II antigens are expressed by a few
types of antigen-presenting cells, namely B-lymphocytes,
macrophages, dendritic cells, thymic epithelial cells, and
activated T lymphocytes [6,7]. The MHC locus has been
associated with more diseases than any other region of the
human genome with more than 20,000 research articles
published [8], and most of the significant associations
were with the class II polymorphisms [5,7].
The HLA class II region contains five isotypes, HLA-DM, -
DO, -DP, -DQ and -DR, all of which are heterodimers
composed of α and β chains [7]. There are only few poly-
morphisms in the HLA-DM and -DO isoforms. On the
other hand, HLA-DP, -DQ and -DR are quite polymorphic
[7]. For HLA-DQ, both the α and β chains, which are
expressed by HLA-DQA1 and -DQB1 genes, respectively,
contribute to the variability. For HLA-DRB, only the β
chain, which is expressed by the HLA-DRB1 gene, contrib-
utes to the variability [7]. HLA-DRB1 (β chain) has
another functional isoform, DRB3-5, whose genes are
located close to the -DRB1 gene. Only one allele in each
individual is expressed from DRB3, 4 and 5 genes com-
bined [7]. HLA-DQ and -DR proteins are responsible for
presenting foreign peptide antigens from infectious
agents, such as bacteria, viruses or autoimmune antigens,
to CD4 T-cells. These antigens stimulate CD4 T-cell
responses that activate B-cells and macrophages. The
structure of the HLA-DQ or -DR peptide-binding groove
varies considerably depending on which DQA1, DQB1
and DRB1 alleles are being exposed [9]. These genetic dif-
ferences may affect the immune response by increasing or
decreasing the ability of HLA-DQ or -DR molecules to
bind and properly present foreign antigens to the CD4 T-
cell [7,10].
Several association studies between HLA polymorphisms
and AAAs have been performed [11-19]. The sample sizes
of these studies, however, were small and the results were
inconsistent. The aim of the current study was to investi-
gate further the role of autoimmunity in the etiology of
AAAs by carrying out a genetic association study with the
HLA-DQA1, -DQB1, and -DRB polymorphisms for AAA.
Methods
Study population
A definition of AAA by Johnston et al [20] (a diameter of
infrarenal aorta ≥ 3 cm) was used. These standards have
also been used by other investigators [21-23]. Altogether
387 unrelated AAA cases (males: 316, 81.7%), 180 Bel-
gian (males: 161, 89.4%), admitted to University Hospital
of Liège in Liège, and 207 Canadian (males: 155, 74.9%),
admitted to Dalhousie University Hospital in Halifax,
were entered into the study. Seventeen patients were
admitted for emergency repair of ruptured AAA and 335
patients were admitted for elective surgery. Thirty-five
patients were diagnosed with AAA using ultrasonography
and were not operated on due to old age or because the
size of the aneurysm was relatively small (< 5 cm). Alto-
gether 152 cases (39.3%) had a family history of AAA,
which was defined as having at least one first-degree rela-
tive affected with AAA. All patients were Caucasian.
Control samples were obtained from 426 Caucasians
(males: n = 217, 50.9%; 269 Belgian and 157 Canadian)
and included spouses of AAA cases (n = 114; all Canadian;
4 males, 110 females), or individuals admitted to the
same hospitals for reasons other than AAA (n = 312; 183
Belgian males, 86 Belgian females; 29 Canadian males
and 14 Canadian females).
The study was approved by the Institutional Review
Boards of Wayne State University School of Medicine and
each patient recruiting center. All subjects gave informed
written consent to participate into the study.
Genotyping
Genomic DNA was isolated from peripheral blood using
a Puregene kit (Gentra Systems, Minneapolis, MN).
Before performing genotyping PCR, a whole-genome
amplification using primer extension preamplification
(PEP) was carried out to increase the amount of template
DNA available for genotyping and to ensure that limited
resources are used cost-effectively [24]. The performance
of PEP in subsequent genotyping reactions was validated
extensively in our laboratory previously [24]. The PEP
products were diluted 100-fold and used for genotyping.
Throughout the manuscript we use the gene symbolsBMC Medical Genetics 2006, 7:67 http://www.biomedcentral.com/1471-2350/7/67
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approved by the HUGO Gene Nomenclature Committee
[25].
HLA-DQA1, -DQB1, -DRB1 and -DRB3-5 alleles were
determined by PCR and single-strand oligonucleotide
probe hybridization assay. HLA-DQA1 alleles were deter-
mined according to Kimura et al [26]. Quality control
samples, including positive and negative controls, were
included in each set of 96 samples run in genotyping reac-
tions. Positive controls included samples whose HLA gen-
otypes were known. HLA-DQA1 was amplified using
primers DQAP1 (5'-ATGGTGTAAACTTGTACCAGT-3')
and DQAP2 (5'-TTGGTAGCAGCGGTAGAGTTG-3') to
generate a 230-bp fragment. Fourteen single-strand oligo-
nucleotide probes discriminated between HLA-
DQA1*0101/0104, *0102, *0103, *0201, *03011/0302,
*03012, *0401, *0501 and *0601 alleles. HLA-DQB1
alleles were determined as previously described [27].
HLA-DQB1 was amplified using primers DQP14 (5'-TGT-
GCTACTTCACCAACGGG-3') and DQP5 (5'-GGTAGTT-
GTGTCTGCACAC-3') to generate a 210-bp fragment.
Twenty-five single-strand oligonucleotide probes could
discriminate between HLA-DQB1*0201/0202, *0301,
*0302, *03031, *03032 *0304, *0305, *0401, *0402,
*0501, *0502, *0503, *0504, *0601, *0602, *0603,
*0604, *0605, *0606, *0607 and *0608 alleles. Both
HLA-DRB1 and DRB3-5 alleles were amplified using
primers GH46 (5'-CCGGATCCTTCGTGTCCCCACAG-
CACG-3') and P2A (5'-TCGCCGCTGCACTGTGAAGC-3')
to generate a 290-bp fragment. Forty single-strand oligo-
nucleotide probes could discriminate between HLA-
DRB1*0101, *0102, *0103, *0301/0303, *0302, *0401,
*0402, *0403, *0404, *0405, *0406, *0407, *0408,
*0409, *0410, *0411, *0412, *0413, *0414, *0415,
*0701/0702, *0801, *0802, *0803, *0804, *0805,
*0806, *0901, *1001, *1101, *1102, *1103, *1104,
*1105, *1201, *1202, *1301, *1302, *1303, *1304,
*1305, *1306, *1401, *1402, *1403, *1404, *1405,
*1406, *1407, *1408, *1409, *1410, *1501, *1502,
*1503, *1601 and *1602 as well as DRB3*0101, *0201,
*0202, *0301, DRB4*0101, DRB5*0101, *0102, *0201/
0202 and *0203 alleles [26]. Samples whose hybridiza-
tion pattern failed to match with the pattern of a known
allele were classified as "could not be determined". Excep-
tions were the unknown alleles which could be classified
into two possible alleles, such as HLA-DRB1*0403 or
*0407, but could not be classified into one particular
allele, and were then designated as "*0403 or *0407".
Two individuals (T.O. and L.G.) scored the results inde-
pendently and discrepancies were resolved by re-evalua-
tion of the raw data or repeating the experiment, if
necessary.
Statistical analyses
First, the distributions of allele frequencies between the
Belgian and Canadian control groups were compared.
Asymptotic p-values were obtained using the χ2 test for
association. Because of the large number of alleles at each
locus, we also obtained empirical p-values for the test of
association for each allele using a permutation test for the
entire table (called the T1 test statistic as opposed to other
test statistics computed by this program that collapses the
table in various ways) as implemented in the computer
program CLUMP [28]. In this permutation test, the popu-
lation group is permuted numerous times, and the test
statistic is recomputed for each permutation. The
observed test statistic is then compared to the distribution
of the permuted test statistics to obtain an empirical p-
value. Significant differences between the two control
groups for all of the HLA loci were found. The p-values
were: 0.062 (empirical: 0.056) for DQA; 0 (empirical:
0.0001) for DQB, 0.008 (empirical: 0.0046) for DRB, and
0 (empirical: 0.0001) for DRB3-5. Canadian and Belgian
populations were, therefore, analyzed separately. To eval-
uate the association between alleles and AAA, the same
approach was used. The Haplo.stats program [29] was
used to estimate haplotype frequencies via the expecta-
tion-maximization (EM) algorithm for HLA-DQA1, -
DQB1, -DRB1 and -DRB3-5 alleles, and to compute two
score tests of association between disease status and HLA
haplotype: 1) global score statistics and 2) haplotype-spe-
cific score statistics. Rare haplotypes with frequencies ≤
0.01 were pooled into a single baseline group. The score
test is developed under the generalized linear model
framework, where the score function is the first derivative
of the log-likelihood from the exponential family distri-
bution. The variance matrix is determined by the matrix of
negative second partial derivative of the log-likelihood.
Using the results from the EM algorithm, the score statis-
tics S = UTV-1U are evaluated under the null hypothesis,
which asymptotically has a chi-square distribution.
Empirical p-values are obtained for the score statistics
using permutation. Results on haplotypes with only two
loci are reported, since the contingency table for 3- or 4-
locus results was sparse given the large number of alleles
at each locus. Analyses were also conducted stratified by
sex, and the presence of a positive family history. Pairwise
measures of linkage disequilibrium (LD) were estimated
using the observed genotypes for the four HLA loci using
the GOLD program [30]. All measures of D' were between
0.26 and 0.37, indicating comparatively low LD between
loci. Correction for multiple testing was applied to the
most significant p-values using the Sidak function.
Post hoc power calculations
Since the HLA locus has a large number of alleles and the
allele frequencies are variable across populations, we
computed power for the locus based on the frequencyBMC Medical Genetics 2006, 7:67 http://www.biomedcentral.com/1471-2350/7/67
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observed in the samples. Power calculations were per-
formed using the power calculator for binomial propor-
tions in Splus 7.0 (Insightful Corporation, Seattle, WA)
for a test of the null hypothesis that p1 = p2, where p1 is
the allele frequency in cases and p2 is the allele frequency
in controls, versus the alternative hypothesis that the
allele frequencies for the cases and controls are different.
To obtain 80% power with the risk allele frequency of
0.208 in the cases and 0.124 in the controls, we needed
331 subjects per group for an α of 0.05, and 460 subjects
per group for an α of 0.0125 (to account for multiple test-
ing).
Results
HLA-DQA1, -DQB1, -DRB1 and -DRB3-5 allele frequen-
cies are summarized in Tables 1, 2, 3, 4. Empirical p-val-
ues obtained by permutation test and asymptotic p-values
obtained by χ2 test are shown in Table 5. Results are
shown separately for the Belgian and Canadian popula-
tions for two reasons: 1) comparison of the distribution of
allele frequencies between the Belgian and Canadian con-
trol groups using a chi-square test showed significant dif-
ferences for all of the HLA loci. The p-values were: 0.062
(empirical: 0.056) for DQA; 0 (empirical: 0.0001) for
DQB, 0.008 (empirical: 0.0046) for DRB, and 0 (empiri-
cal: 0.0001) for DRB3-5; and 2) in our previous work we
showed highly significant departure from Hardy-Wein-
berg proportions for several markers in the combined
sample, but not in the subsets, indicating evidence for the
presence of population stratification [31]. There was a
nominally significant association between AAA and HLA-
DQA1 locus in the Belgian population (empirical p =
0.039; asymptotic p = 0.049; p = 0.147 after Sidak correc-
tion for multiple testing). In particular, the frequency of
the HLA-DQA1*0102 allele was significantly increased in
the AAA group (75/360 alleles, 20.8%) compared to the
Table 1: HLA-DQA1 allele frequencies in AAA cases and controls
AAA Cases Controls
Male Female Total Male Female Total
DQA1 
alleles
na %n a %n a %n a %n a %n a %
Belgian
*0101/
0104
4 51 4 . 0 4 1 0 . 54 91 3 . 66 81 9 . 12 21 3 . 39 01 7 . 2
*0102 67 20.8b 82 1 . 1 7 5 2 0 . 8 c 44 12.4b 27 16.3 71 13.6c
* 0 1 0 32 57 . 8 1 2 . 62 67 . 23 6 1 0 . 18 4 . 84 48 . 4
* 0 2 0 1 5 31 6 . 5 3 7 . 9 5 61 5 . 64 61 2 . 91 91 1 . 46 51 2 . 5
*03011/
0302
3 71 1 . 5 5 1 3 . 24 21 1 . 75 41 5 . 23 01 8 . 18 41 6 . 1
* 0 3 0 1 2 000000001 0 . 6 1 0 . 2
*0401 8 2.5 3 7.9 11 3.1 11 3.1 8 4.8 19 3.6
*0501 87 27.0 14 36.8 101 28.1 97 27.2 49 29.5 146 28.0
* 0 6 0 1 000000002 1 . 2 2 0 . 4
Total 322 100.0 38 100.0 360 100.0 356 100.0 166 100.0 522 100.0
Canadian
*0101/
0104
46 14.9 7 7.3 53 13.1 12 18.2 42 17.1 54 17.3
* 0 1 0 2 5 81 8 . 82 02 0 . 87 81 9 . 31 11 6 . 73 71 5 . 04 81 5 . 4
* 0 1 0 3 1 1 3 . 677 . 3 1 8 4 . 646 . 1 1 5 6 . 1 1 9 6 . 1
* 0 2 0 1 4 81 5 . 61 71 7 . 76 51 5 . 81 72 5 . 83 41 3 . 85 11 6 . 3
*03011/
0302
66 21.4 19 19.8 85 21.0 12 18.2 51 20.7 63 20.2
* 0 3 0 1 2 000000000000
* 0 4 0 172 . 322 . 192 . 211 . 593 . 7 1 0 3 . 2
*0501 71 23.1 24 25.0 95 23.5 9 13.6 57 23.2 66 21.2
* 0 6 0 110 . 30 0 10 . 20 0 10 . 410 . 3
Total 308 100.0 96 100.0 404 100.0 66 100.0 246 100.0 312 100.0
AAA: abdominal aortic aneurysm.
a Number of alleles.
b Empirical P = 0.019, asymptotic P = 0.003 for comparison of this particular allele versus all other alleles combined between cases and controls 
among Belgian males.
c Empirical P = 0.033, asymptotic P = 0.005 for comparison of this particular allele versus all other alleles combined between cases and controls 
among Belgians.BMC Medical Genetics 2006, 7:67 http://www.biomedcentral.com/1471-2350/7/67
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control group (71/522 alleles, 13.6%) in the Belgian pop-
ulation (empirical p = 0.033; asymptotic p = 0.005; Table
1). No significant associations were found in the Cana-
dian population (Tables 1, 2, 3, 4, 5), but this might be
due to lower power to detect such associations because of
smaller sample size.
The results on analyses in which the AAA cases and con-
trols were stratified by sex are shown in Table 5. The HLA-
DQA1 allele frequencies in AAA cases and controls in the
Belgians stratified by sex are shown in Table 1. The associ-
ation between AAA and HLA-DQA1 locus remained nom-
inally significant only in the Belgian male population
(empirical p = 0.027; asymptotic p = 0.071; p = 0.104 after
Sidak correction for multiple testing). There was a signifi-
cant increase in the frequency of the HLA-DQA1*0102
allele among AAA cases (67/322 alleles, 20.8%) com-
pared to controls (44/356 alleles, 12.4%) in the Belgian
Table 2: HLA-DQB1 allele frequencies in AAA cases and controls
AAA Cases Controls
Male Female Total Male Female Total
DQB1 allelesa nb %n b %n b %n b %n b %n b %
Belgian
*0201/0202 62 19.4 5 15.2 67 19.0 72 21.4 36 21.8 108 21.5
* 0 3 0 1 5 91 8 . 5 9 2 7 . 26 81 9 . 36 82 0 . 24 62 7 . 9 1 1 4 2 2 . 7
* 0 3 0 2 3 2 1 0 . 03 9 . 13 5 1 0 . 0 2 05 . 91 06 . 13 06 . 0
* 0 3 0 3 1 0000007 2 . 1 2 1 . 2 9 1 . 8
*03032 10 3.1 0 0 10 2.8 8 2.4 5 3.0 13 2.6
* 0 3 0 4 82 . 539 . 1 1 1 3 . 172 . 142 . 4 1 1 2 . 2
* 0 3 0 5 3 0 . 9 003 0 . 9 1 0 . 3 001 0 . 2
*0401 10 3.1 3 9.1 13 3.7 10 3.0 8 4.8 18 3.6
* 0 5 0 1 4 01 2 . 5 4 1 2 . 14 41 2 . 55 61 6 . 61 5 9 . 1 7 11 4 . 1
* 0 5 0 2 72 . 20 0 72 . 051 . 542 . 491 . 8
* 0 5 0 3 92 . 80 0 92 . 682 . 474 . 2 1 5 3 . 0
* 0 6 0 1 0000001 0 . 3 001 0 . 2
* 0 6 0 2 4 1 1 2 . 91 3 . 04 2 1 2 . 0 2 47 . 11 48 . 53 87 . 6
*0603 23 7.2 3 9.1 26 7.4 33 9.8 6 3.6 39 7.8
*0604 13 4.1 2 6.1 15 4.3 12 3.6 5 3.0 17 3.4
*0605/0609 1 0.3 0 0 1 0.3 3 0.9 2 1.2 5 1.0
* 0 6 0 6 000000001 0 . 6 1 0 . 2
* 0 6 0 7 1 0 . 3 001 0 . 3 2 0 . 6 002 0 . 4
Total 319 100.0 33 100.0 352 100.0 337 100.0 165 100.0 502 100.0
Canadian
*0201/0202 77 25.1 26 25.5 103 25.2 19 28.8 63 25.6 82 26.3
*0301 54 17.6 20 19.6 74 18.1 9 13.6 42 17.1 51 16.3
*0302 35 11.4 11 10.8 46 11.2 8 12.1 30 12.2 38 12.2
* 0 3 0 3 1 5 1 . 6 005 1 . 2 001 0 . 4 1 0 . 3
* 0 3 0 3 2 1 6 5 . 254 . 9 2 1 5 . 146 . 062 . 4 1 0 3 . 2
* 0 3 0 4 4 1 . 3 004 1 . 0 003 1 . 2 3 1 . 0
* 0 3 0 5 000000000000
* 0 4 0 1 62 . 011 . 071 . 711 . 583 . 392 . 9
*0501 38 12.4 8 7.8 46 11.2 8 12.1 33 13.4 41 13.1
* 0 5 0 2 6 2 . 0 1 1 . 0 7 1 . 7 000000
* 0 5 0 3 82 . 611 . 092 . 234 . 593 . 7 1 2 3 . 8
*0601 2 0.7 1 1.0 3 0.7 0 0 1 0.4 1 0.3
*0602 31 10.1 18 17.6 49 12.0 9 13.6 25 10.2 34 10.9
*0603 12 3.9 6 5.9 18 4.4 4 6.0 14 5.7 18 5.8
* 0 6 0 4 1 0 3 . 332 . 9 1 3 3 . 211 . 593 . 7 1 0 3 . 2
*0605/0609 3 1.0 1 1.0 4 1.0 0 0 1 0.4 1 0.3
* 0 6 0 6 000000000000
* 0 6 0 7 000000001 0 . 4 1 0 . 3
Total 307 100.0 102 100.0 409 100.0 66 100.0 246 100.0 312 100.0
AAA: abdominal aortic aneurysm.
a Alleles *0402, *0504 and *0608 were also assayed but were not present in either population.
b Number of alleles.BMC Medical Genetics 2006, 7:67 http://www.biomedcentral.com/1471-2350/7/67
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Table 3: HLA-DRB1 allele frequencies in AAA cases and controls
AAA Cases Controls
Male Female Total Male Female Total
DRB1 allelesa nb %n b %n b %n b %n b %n b %
Belgian
*0101 29 9.1 3 8.3 32 9.0 39 10.9 14 8.3 53 10.1
*0102 7 2.2 1 2.8 8 2.2 7 2.0 4 2.4 11 2.1
* 0 1 0 3 1 0 . 3 1 2 . 8 2 0 . 6 000000
*0301/0303 5 1.6 1 2.8 6 1.7 7 2.0 9 5.4 16 3.0
*0302 22 6.9 2 5.6 24 6.7 27 7.5 8 4.8 35 6.7
*0401 11 3.4 3 8.3 14 3.9 20 5.6 10 6.0 30 5.7
* 0 4 0 2 10 . 3 00 10 . 310 . 321 . 230 . 6
*0403 7 2.2 2 5.6 9 2.5 13 3.6 5 3.0 18 3.4
*0404 9 2.8 0 0 9 2.5 10 2.8 6 3.6 16 3.0
* 0 4 0 5 00 0 0004 1 . 1 004 0 . 8
* 0 4 0 7 20 . 6 00 20 . 620 . 610 . 630 . 6
* 0 4 0 8 00 0 0001 0 . 3 001 0 . 2
* 0 4 1 0 1 0 . 3 0 01 0 . 3 000000
* 0 4 1 3 30 . 9 00 30 . 810 . 310 . 620 . 4
*0701/0702 54 16.9 3 8.3 57 16.0 51 14.2 18 10.7 69 13.1
*0801 9 2.8 3 8.3 12 3.4 11 3.1 6 3.6 17 3.2
*0802 0 0 0 0 0 0 1 0.3 2 1.2 3 0.6
*0803 1 0.3 0 0 1 0.3 0 0 2 1.2 2 0.4
* 0 8 0 5 00 0 000000000
* 0 9 0 1 41 . 3 00 41 . 151 . 421 . 271 . 3
*1001 3 0.9 0 0 3 0.8 7 2.0 0 0 7 1.3
*1101 41 12.8 8 22.2 49 13.8 38 10.6 25 14.9 63 12.0
*1102 0 0 0 0 0 0 2 0.6 1 0.6 3 0.6
* 1 1 0 3 72 . 2 1 2 . 882 . 241 . 110 . 651 . 0
*1104 1 0.3 0 0 1 0.3 1 0.3 0 0 1 0.2
* 1 2 0 1 30 . 9 1 2 . 841 . 161 . 70 0 61 . 1
*1301 14 4.4 3 8.3 17 4.8 10 2.8 1 0.6 11 2.1
*1302 18 5.6 1 2.8 19 5.3 34 9.5 13 7.7 47 8.9
* 1 3 0 3 30 . 9 00 30 . 830 . 842 . 471 . 3
* 1 3 0 5 00 0 000000000
* 1 4 0 1 51 . 6 00 51 . 451 . 410 . 661 . 1
* 1 4 0 7 30 . 9 00 30 . 861 . 731 . 891 . 7
*1501 0 0 0 0 0 0 1 0.3 2 1.2 3 0.6
* 1 5 0 2 1 0 . 3 0 01 0 . 3 000000
*1601 47 14.7 2 5.6 49 13.8 27 7.5 19 11.3 46 8.7
* 1 6 0 2 00 0 0002 0 . 6 002 0 . 4
*0301/0303 or *0302 1 0.3 0 0 1 0.3 2 0.6 3 1.8 5 1.0
*0403 or *0407 0 0 0 0 0 0 1 0.3 1 0.6 2 0.4
*0404 or *0408 0 0 0 0 0 0 0 0 1 0.6 1 0.2
* 1 1 0 1  o r  * 1 1 0 4 00 0 000000000
* 1 3 0 1  o r  * 1 3 0 2 72 . 2 1 2 . 882 . 251 . 421 . 271 . 3
*1401 or *1407 0 0 0 0 0 0 2 0.6 1 0.6 3 0.6
C N D 00 0 0002 0 . 6 002 0 . 4BMC Medical Genetics 2006, 7:67 http://www.biomedcentral.com/1471-2350/7/67
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Total 320 100.0 36 100.0 356 100.0 358 100.0 168 100.0 526 100.0
Canadian
*0101 27 8.8 7 7.0 34 8.3 4 6.1 21 8.5 25 8.0
* 0 1 0 2 10 . 3 1 1 . 020 . 523 . 041 . 661 . 9
* 0 1 0 3 61 . 9 1 1 . 071 . 723 . 041 . 661 . 9
*0301/0303 13 4.2 2 2.0 15 3.7 3 4.5 7 2.8 10 3.2
*0302 26 8.4 12 12 38 9.3 2 3.0 23 9.3 25 8.0
*0401 31 10.0 8 8.0 39 9.6 6 9.1 28 11.3 34 10.8
* 0 4 0 2 2 0 . 6 0 02 0 . 5 000000
*0403 8 2.6 7 7.0 15 3.7 3 4.5 7 2.8 10 3.2
*0404 17 5.5 4 4.0 21 5.1 3 4.5 11 4.4 14 4.5
* 0 4 0 5 00 0 000002 0 . 8 2 0 . 6
* 0 4 0 7 1 0 . 3 2 2 . 0 3 0 . 7 000000
* 0 4 0 8 1 0 . 3 0 01 0 . 2 000000
* 0 4 1 0 00 0 000000000
* 0 4 1 3 00 0 000000000
*0701/0702 49 15.9 18 18 67 16.4 18 27.3 36 14.5 54 17.2
* 0 8 0 1 72 . 3 1 1 . 082 . 00 0 62 . 461 . 9
* 0 8 0 2 0 01 1 . 010 . 20 0 20 . 820 . 6
* 0 8 0 3 00 0 000001 0 . 4 1 0 . 3
* 0 8 0 5 00 0 0001 1 . 5 001 0 . 3
*0901 7 2.3 0 0 7 1.7 0 0 2 0.8 2 0.6
*1001 3 1.0 0 0 3 0.7 0 0 3 1.2 3 1.0
*1101 22 7.1 7 7.0 29 7.1 3 4.5 21 8.5 24 7.6
*1102 1 0.3 0 0 1 0.2 0 0 1 0.4 1 0.3
* 1 1 0 3 1 0 . 3 1 1 . 0 2 0 . 5 000000
* 1 1 0 4 00 0 000000000
* 1 2 0 1 0 01 1 . 010 . 20 0 31 . 231 . 0
*1301 8 2.6 3 3.0 11 2.7 1 1.5 1 0.4 2 0.6
*1302 12 3.9 8 8.0 20 4.9 3 4.5 21 8.5 24 7.6
* 1 3 0 3 3 1 . 0 0 03 0 . 7 000000
*1305 1 0.3 0 0 1 0.2 0 0 1 0.4 1 0.3
* 1 4 0 1 51 . 6 00 51 . 223 . 020 . 841 . 3
* 1 4 0 7 20 . 6 00 20 . 511 . 562 . 472 . 2
* 1 5 0 1 00 0 00000 0 000
* 1 5 0 2 00 0 000000000
*1601 42 13.6 15 15 57 14.0 9 13.6 29 11.7 38 12.1
* 1 6 0 2 00 0 000000000
*0301/0303 or *0302 4 1.3 0 0 4 1.0 1 1.5 2 0.8 3 1.0
* 0 4 0 3  o r  * 0 4 0 7 1 0 . 3 0 01 0 . 2 000000
* 0 4 0 4  o r  * 0 4 0 8 00 1 1 . 0 1 0 . 2 000000
* 1 1 0 1  o r  * 1 1 0 4 1 0 . 3 0 01 0 . 2 000000
*1301 or *1302 4 1.3 0 0 4 1.0 1 1.5 1 0.4 2 0.6
*1401 or *1407 1 0.3 0 0 1 0.2 1 1.5 2 0.8 3 1.0
C N D 10 . 3 00 10 . 20 0 10 . 410 . 3
Total 308 100.0 100 100.0 408 100.0 66 100.0 248 100.0 314 100.0
AAA: abdominal aortic aneurysm; CND: could not be determined.
a Alleles *0406, *0409, *0411, *0412, *0414, *0415, *0804, *0806, *1105, *1202, *1304, *1306, *1402, *1403, *1404, *1405, *1406, *1408, 
*1409,*1410 and *1503 were also assayed but were not present in either population.
b Number of alleles.
c Could be classified into two possible alleles, but could not be classified into one particular allele.
Table 3: HLA-DRB1 allele frequencies in AAA cases and controls (Continued)BMC Medical Genetics 2006, 7:67 http://www.biomedcentral.com/1471-2350/7/67
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male population (empirical p = 0.019; asymptotic p =
0.003). The odds ratio was 1.86 and 95% confidence
interval was 1.56 to 2.22 for the HLA-DQA1*0102 allele
versus all the other alleles in the Belgian males. Since the
number of female cases was small, no conclusions can be
drawn about the association in females. In the Belgian
population, the association between AAA and DQA1 was
greater among those with a family history of AAA (empir-
ical p = 0.069; asymptotic p = 0.067) compared to those
without a family history of AAA (empirical p = 0.157;
asymptotic p = 0.164). Since the proportion of males was
similar in the group with (88%) and without (90%) fam-
ily history, the result was not due to difference in the
number of males in each group. No additional significant
associations were found between AAA cases and controls
when AAA cases were stratified by family history of AAA
(Table 6).
The results of haplotype analyses for the HLA-DQA1, -
DQB1, -DRB1 and -DRB3-5 loci between AAA cases and
controls are shown in Tables 7 and 8. Only the most sig-
nificant haplotypes and their p-values when analyzing
two-locus haplotypes are listed. Although most of the fre-
quencies of the most significant haplotypes were relatively
rare (< 5%), haplotype DQA1*0102/DRB1*1601 had a
relatively high frequency (11.6%; Table 7). Using the glo-
bal score statistics, the nominal p-value was 0.049 and
with haplotype-specific score statistics, the nominal p-
value was 0.002 for this haplotype, which is not as strong
statistical evidence as the result for the DQA1 locus alone.
Table 4: HLA-DRB3-5 allele frequencies in AAA cases and controls
AAA Cases Controls
Male Female Total Male Female Total
DRB3-5 
alleles
na %n a %n a %n a %n a %n a %
Belgian
B3*0101 40 12.5 8 22.2 48 13.5 53 14.8 24 14.4 77 14.6
B3*0201 11 3.4 1 2.8 12 3.4 11 3.1 0 0 11 2.1
B3*0202 63 19.7 8 22.2 71 19.9 86 24.0 35 21.0 121 23.0
B3*0301 34 10.6 7 19.4 41 11.5 45 12.5 22 13.2 67 12.7
B4*0101 94 29.4 7 19.4 101 28.4 103 28.7 52 31.1 155 29.5
B 5 * 0 1 0 1 5 0 1 5 . 62 5 . 65 2 1 4 . 6 3 18 . 61 69 . 64 78 . 9
B 5 * 0 1 0 2 41 . 30 0 41 . 120 . 631 . 851 . 0
B 5 * 0 2 0 1 72 . 20 0 72 . 061 . 710 . 671 . 3
B 5 * 0 2 0 3 00000 0 . 0 000000
B3*0201 
or *0202 
b
13 4.1 1 2.8 14 3.9 20 5.6 10 6.0 30 5.7
C N D 41 . 325 . 661 . 720 . 642 . 461 . 1
Total 320 100.0 36 100.0 356 100.0 359 100.0 167 100.0 526 100.0
Canadian
B3*0101 53 17.2 17 17 70 17.2 9 13.6 38 15.3 47 15.0
B 3 * 0 2 0 1 92 . 955 . 0 1 4 3 . 40 0 62 . 461 . 9
B3*0202 44 14.3 15 15 59 14.5 8 12.1 46 18.5 54 17.2
B 3 * 0 3 0 1 3 81 2 . 31 3 1 3 5 11 2 . 51 11 6 . 73 21 2 . 94 31 3 . 7
B4*0101 108 35.1 32 32 140 34.3 26 39.4 80 32.3 106 33.8
B 5 * 0 1 0 1 4 51 4 . 61 4 1 4 5 91 4 . 51 21 8 . 23 81 5 . 35 01 5 . 9
B 5 * 0 1 0 2 10 . 311 . 020 . 50 0 31 . 231 . 0
B 5 * 0 2 0 1 20 . 611 . 030 . 70 0 10 . 410 . 3
B 5 * 0 2 0 3 1 0 . 3 001 0 . 2 000000
B3*0201 
or *0202 
b
3 1 . 0 003 0 . 7 000000
CND 4 1.3 2 2.0 6 1.5 0 0 4 1.6 4 1.3
Total 308 100.0 100 100.0 408 100.0 66 100.0 248 100.0 314 100.0
AAA: abdominal aortic aneurysm; CND: could not be determined.
a Number of alleles.
b Could be classified into HLA-DRB*0201 or *0202, but could not be classified into one particular allele.BMC Medical Genetics 2006, 7:67 http://www.biomedcentral.com/1471-2350/7/67
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In addition, the haplotype results were not significant
among the Belgian males (Table 8), as was observed for
DQA1 alone.
Discussion
AAA is a relatively common disease in that an estimated
1–6% of the population in industrialized countries har-
bor aneurysms [32]. Rupture of AAAs causes 1–2% of all
deaths in males over 65 years of age in Western countries
[33,34]. It has been suggested that AAAs are a complex dis-
ease [35,36]. Two segregation studies favored a genetic
model in explaining the familial aggregation of AAA and
suggested the presence of a major gene effect [35,36].
Recently, we reported on a collection of 233 families with
at least two individuals affected with AAA [37], and iden-
tified two genetic susceptibility loci for AAA on chromo-
somes 19q13 and 4q31 [38]. We also recently reported a
genetic association study for polymorphisms in biologi-
cally relevant candidate genes for AAA, and found evi-
dence for an association between tissue inhibitor of
metalloproteinases 1 (TIMP1) polymorphisms and AAA
[31].
It is well known that there are large differences in the fre-
quencies of the HLA polymorphisms in different popula-
tions. We, therefore, carried out the analyses with Belgian
and Canadian populations separately, to avoid potential
false positive results because of population stratification.
There have, however, been several examples where sub-
structure within Caucasian samples has been explored
and identified [39,40], thus the possibility of cryptic sub-
structure within each population remains a concern.
Although ancestry informative marker (AIM) panels exist,
these panels have been created with the intent of distin-
guishing the major racial/ethnic groups, and may not be
sensitive for detecting population substructure within a
single racial/ethnic group. Ideally, it will be possible in the
future to utilize AIM panels that are specific to addressing
the question of cryptic relatedness within the Caucasian
population.
We observed a potential association between the HLA-
DQA1 locus and AAA among the Belgian males. In partic-
ular, there was a statistically significant difference in the
frequency of the HLA-DQA1*0102 allele between AAA
Table 6: Analysis of HLA loci in AAA cases and controls when stratified by family history of AAA
Locus Belgian Canadian
Family history No family history Family history No family history
EPa APb EPa APb EPa APb EPa APb
DQA1 0.069 0.067 0.157 0.164 0.198 0.284 0.764 0.832
DQB1 0.419 0.415 0.305 0.317 0.384 0.532 0.432 0.571
DRB1 0.597 0.811 0.099 0.171 0.232 0.545 0.242 0.659
DRB3-5 0.356 0.454 0.314 0.414 0.831 0.796 0.490 0.581
AAA: abdominal aortic aneurysm; EP: empirical p-value; AP: asymptotic p-value.
a Global empirical p-values were calculated by permutation test using the CLUMP [28] program.
b Asymptotic p-values were calculated by χ2 test.
Table 5: Empirical and asymptotic p-values for comparisons between AAA cases and controls within each population and stratified by 
sex
Locus Belgian Canadian
Malea Femalea Total Malea Femalea Total
EPb APc EPb APc EPb APc EPb APc EPb APc EPb APc
DQA1 0.027 0.071 0.899 0.900 0.039 0.049 0.392 0.487 0.340 0.443 0.589 0.682
DQB1 0.083 0.130 0.495 0.710 0.129 0.144 0.917 0.972 0.405 0.553 0.371 0.510
DRB1 0.252 0.375 0.218 0.653 0.114 0.200 0.465 0.890 0.408 0.864 0.246 0.545
DRB3-5 0.145 0.217 0.239 0.308 0.217 0.308 0.745 0.778 0.926 0.952 0.766 0.739
AAA: abdominal aortic aneurysm; EP: empirical p-value; AP: asymptotic p-value.
a Number of Belgian AAA cases: Male = 161, Female = 19; Canadian AAA cases: Male = 155, Female = 52; Belgian controls: Male = 178, Female = 
91; Canadian controls: Male = 39, Female = 118.
b Global empirical p-values were calculated by permutation test using the CLUMP [28] program.
c Asymptotic p-values were calculated by χ2 test.BMC Medical Genetics 2006, 7:67 http://www.biomedcentral.com/1471-2350/7/67
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Table 8: Haplotype analyses for two HLA loci combined and stratified by population and sex
Population Sex Haplotype 
combination
Global Score 
Statistics
DF p value Most significant haplotype Haplotype-specific 
score statisticsa
p valuea
Haplotype Population 
frequency (%)
Belgian
Male DQA1+DQB1 54.0 42 0.102 0102~0602 9.4 2.97 0.003
DQA1+DRB1 57.8 53 0.303 0102~1601 10.5 3.50 0.001
DQA1+DRB3-5 44.8 39 0.240 0102~B5-0101 9.4 2.95 0.003
DQB1+DRB1 81.1 82 0.508 0602~1601 8.9 2.88 0.004
DQB1+DRB3-5 53.5 60 0.710 0602~B5-0101 9.2 2.88 0.004
DRB1+DRB3-5 84.5 81 0.374 1601~B5-0101 9.3 3.24 0.001
Female DQA1+DQB1 29.7 28 0.380 0102~0603 1.3 3.48 0.001
DQA1+DRB1 41.6 34 0.173 0102~1301 2.1 3.52 0.001
DQA1+DRB3-5 22.9 26 0.638 0501~B3-0201 0.6 2.12 0.033
DQB1+DRB1 40.7 49 0.794 0604~1301 2.2 2.81 0.005
DQB1+DRB3-5 38.0 37 0.422 0603~B5-0101 0.6 2.74 0.006
DRB1+DRB3-5 49.4 48 0.418 1301~B3-0301 2.2 2.92 0.003
Canadian
Male DQA1+DQB1 27.6 32 0.691 0101~0201 0.3 -2.16 0.031
DQA1+DRB1 36.8 38 0.527 0101~0102 0.8 -2.34 0.020
DQA1+DRB3-5 27.8 33 0.724 0401~B5-0101 0.3 -2.00 0.046
DQB1+DRB1 55.7 56 0.486 0501~0102 0.8 -2.22 0.027
DQB1+DRB3-5 36.3 49 0.910 03032~B3-0301 1.1 -3.32 0.001
DRB1+DRB3-5 55.6 63 0.735 0701~B4-0101 11.4 -2.19 0.028
Female DQA1+DQB1 29.1 31 0.563 0201~0302 1.2 2.01 0.045
DQA1+DRB1 41.4 38 0.326 0103~1301 0.4 2.25 0.024
DQA1+DRB3-5 34.1 33 0.414 0102~B3-0101 0.6 2.37 0.018
DQB1+DRB1 69.6 62 0.237 0302~0407 0.5 2.71 0.007
DQB1+DRB3-5 49.0 43 0.245 0602~B4-0101 0.9 2.93 0.003
DRB1+DRB3-5 61.1 60 0.437 0301~B3-0301 0.2 2.37 0.017
DF: degrees of freedom; AAA: abdominal aortic aneurysm.
a Haplo.stats program [29] was used for the analyses. Rare haplotype with frequencies ≤ 0.01 were pooled into a single baseline group. Results on 
haplotypes with only two loci are reported.
Table 7: Haplotype analyses when comparing two HLA loci
Haplotype 
combination
Global Score 
Statistics
DF p value Most significant haplotype Haplotype-
specific score 
statisticsa
p valuea
Haplotype Population 
Frequency (%)
DQA1+DQB1 62.7 58 0.311 0201~0302 1.2 3.01 0.003
DQA1+DRB1 91.8 71 0.049 0102~1601 11.6 3.04 0.002
DQA1+DRB3-5 50.6 51 0.491 0101~B3-0202 4.8 -2.39 0.017
DQB1+DRB1 125.7 119 0.319 0604~1301 1.1 2.36 0.018
DQB1+DRB3-5 66.2 77 0.806 0301~B3-0201 1.9 2.02 0.044
DRB1+DRB3-5 115.1 114 0.453 1601~B5-0101 10.3 2.35 0.019
DF: degrees of freedom; AAA: abdominal aortic aneurysm.
a Haplo.stats program [29] was used for the analysis. Rare haplotypes with frequencies of ≤ 0.01 were pooled into a single baseline group. Results 
on haplotypes with only two loci are reported.BMC Medical Genetics 2006, 7:67 http://www.biomedcentral.com/1471-2350/7/67
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cases and controls in the Belgian males. This finding sug-
gests that the HLA-DQA1 locus harbors a genetic risk fac-
tor for AAAs. Since the number of the Belgian female cases
was small (n = 20), further work with a larger sample will
be needed to investigate the role of HLA in female AAA
cases. No significant associations were observed in the
Canadian population, although the frequency of the
DQA1*0102 allele was also higher in the Canadian cases
than the controls.
Several association studies between HLA polymorphisms
and AAA have been performed previously. Most of the
previous studies were small and different methods to type
the HLA alleles were used making it difficult to compare
these studies to each other (Table 9) [11-19]. The most
common finding was an association between AAA and
HLA-DRB1*02 alleles, which are divided into -DRB1*15
and *16 alleles. Tilson et al [12] demonstrated this associ-
ation in 26 African-Americans. Rasmussen et al [13,16,17]
reported a similar result in 37 North Americans and
Hirose et al [14] reported this association in 46 Japanese.
Sugimoto et al [18] (n = 49) and Moňux et al [19] (n =
72), however, failed to find such an association in their
studies. Our study showed a marginally significant associ-
ation between haplotype DQA1*0102/DRB1*1601 and
AAA. The HLA-DRB1*1601 allele, however, was not sig-
nificantly associated with AAA by permutation test
(empirical p = 0.253; asymptotic p = 0.02). There was no
significant association between HLA-DRB1*04 alleles and
AAA in the current study, which differs from the results by
Rasmussen et al [13] and Moňux et al [19] when using 37
and 72 AAA cases, respectively. No prior association stud-
ies between AAA and HLA-DQA1 locus were performed
(Table 9).
The HLA-DQA1*0102 allele, which showed a potential
association with AAA in our study, has been found to be
associated previously with other diseases. The HLA-
DQA1*0102 allele is known to be a protective allele
against type 1 diabetes mellitus (DM) and systemic lupus
erythematosus, which are classical autoimmune diseases
[41,42]. Interestingly, type 2 DM, which is a well-known
risk factor for many cardiovascular diseases, is protective
against AAA in the U.S. population [23].
Although there is growing evidence of the association
between the HLA system and autoimmune diseases,
including AAA, the precise disease-causing mechanism is
yet to be defined. It is also possible that an association
between HLA and disease is only a marker for an undis-
covered polymorphism in a linked gene. There are at least
120 additional genes in the MHC region. Most of these
additional genes in the HLA class II region are involved in
immunological functions that relate to the HLA class I and
II genes [7,43]. Because of the high density of potentially
important genes in the MHC region, linkage disequilib-
rium around this region makes it difficult to identify the
exact susceptibility gene for a disease.
Limitations of the study were: 1) the statistical power was
relatively low (for significance level of 0.05 the power was
0.49 in the Belgian males; 0.14 in the Belgian females;
0.16 in the Canadian males and 0.22 in the Canadian
females using the observed allele frequencies), and after
correction for multiple testing, none of the results
Table 9: Previous HLA studies on AAA
Study Country n (Inflammatory AAA)a HLA locus studied Significant alleleb p
Norrgård et al 1984 [11] Sweden 48 HLA-A, -Bc None N/A
Tilson et al 1996 [12] US 26 HLA-DRB1 DRB1*02 0.04
DRB1*12 0.02
Rasmussen et al 1997 [13] US 37 HLA-DQB1, DRB1 DRB1*15 <0.05
(37) DRB1*0404 <0.05
Hirose et al 1998 [14] Japan 46 HLA-DRc DR2(15) <0.005
Hirose & Tilson 1999 [15] Japan 36 HLA-DQc DQ3 0.014
Rasmussen et al 2001 [16] US 142 HLA-DRB1 DRB1*02 0.03
(40) 0.01d
Rasmussen et al 2002 [17] US 142 HLA-DRB1 DRB1*02 <0.01
DRB1*08 0.04
DRB1*14 <0.01
Sugimoto et al 2003 [18] Japan 49 HLA-A, -B, -DR A2 <0.05
B61 <0.005
Moňux et al 2003 [19] Spain 72 HLA-DRB1 DRB1*0401 0.02
AAA: abdominal aortic aneurysm.
a Inflammatory AAA was categorized and analyzed separately.
b Allele which had a significantly different frequency between AAA cases and controls.
c Serological typing was carried out.
d P-value for inflammatory AAA.BMC Medical Genetics 2006, 7:67 http://www.biomedcentral.com/1471-2350/7/67
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remained significant. Nevertheless, the findings were con-
sistent in the sense that the HLA-DQA1*0102 allele fre-
quency was always higher in the case groups than in the
control groups (20.8% vs. 12.4% in the Belgian males;
21% vs. 16% in the Belgian females; 18.8% vs. 16.7 in the
Canadian males; and 20.8% vs. 15% in the Canadian
females); 2) although the overall sample size was not
small, the number of alleles was large leading to relatively
small counts for each allele; 3) we did not test the interac-
tion with other loci and environmental factors, such as
age, or smoking; and 4) our sampling scheme including
spousal controls could lead to false positive results
because of the potential effect of the HLA loci on mate
selection. The HLA region has been suggested to influence
mate selection based on odor differences coded by the
MHC genes, with a preference for dissimilar partners, in
both mice and humans [44], although these findings are
not always consistent. The presence of negative assortative
mating could lead to false positive findings when compar-
ing AAA cases to control spouses.
Conclusion
We found evidence for genetic association between the
HLA-DQA1 locus and AAA suggesting that this genomic
region harbors a genetic risk factor for AAAs in the Belgian
male population. The same DQA1*0102 allele was
present at higher frequency among the Belgian female,
Canadian male and Canadian female cases supporting the
hypothesis that autoimmunity contributes to the patho-
genesis of AAAs. In future studies, the findings need to be
assessed in another, larger sample.
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